Clinical Trial Update: Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update describes inetetamab plus chemotherapy with optional PD-1/PD-L1 inhibition for HER2-positive metastatic biliary tract cancer; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Chemotherapy (unspecified)
• Inetetamab (inetetamab)
• PD-1/PD-L1 inhibitor (unspecified)

Snippet

Sponsor: Eastern Hepatobiliary Surgery Hospital | Conditions: Metastatic Biliary Tract Cancer, HER2 Positive | Phase 4 | Status: NOT_YET_RECRUITING